Cost of hemophilia A in Turkey: an economic disease burden analysis

Malhan S., Oksuz E., Antmen B., Ar M. C., BALKAN C., Kavakli K.

JOURNAL OF MEDICAL ECONOMICS, cilt.24, sa.1, ss.1052-1059, 2021 (SCI-Expanded, Scopus)

  • Yayın Türü: Makale / Tam Makale
  • Cilt numarası: 24 Sayı: 1
  • Basım Tarihi: 2021
  • Doi Numarası: 10.1080/13696998.2021.1965388
  • Dergi Adı: JOURNAL OF MEDICAL ECONOMICS
  • Derginin Tarandığı İndeksler: Science Citation Index Expanded (SCI-EXPANDED), Scopus, CINAHL, EMBASE, International Pharmaceutical Abstracts, MEDLINE
  • Sayfa Sayıları: ss.1052-1059
  • Anahtar Kelimeler: Hemophilia A, costs and cost analysis, drug costs, blood coagulation factors, QUALITY-OF-LIFE, CARE, MANAGEMENT, INHIBITORS, IMPACT
  • İstanbul Üniversitesi Adresli: Evet

Özet

Objective: Hemophilia A is the second most common bleeding disorder causing patients to have lifelong follow-up and treatment. Despite being a rare disease, hemophilia A has a high economic burden on individuals and the public. The purpose of this study was to estimate the total disease cost of hemophilia A in Turkey.